专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

CA3057440A1 DNA METHYLATION AND MUTATIONAL ANALYSIS METHODS FOR BLADDER CANCER SURVEILLANCE 未知
公开(公告)号：CA3057440A1
公开(公告)日：2018-11-22
申请号：CA3057440
申请日：2018-05-17
申请人： GENOMIC HEALTH INC
发明人： LOPATIN MARGARITA , TSIATIS ATHANASIOS , SILK CHRISTOPHER N , MILLER DAVID P , CRAGER MICHAEL , FEBBO PHILLIP , KNEZEVIC DEJAN
IPC分类号： C12Q1/6886 , A61K45/00 , A61P35/00 , C12M1/34 , C12Q1/6806 , C12Q1/6809 , C12Q1/6851
摘要： The present disclosure relates to methods of monitoring bladder cancer patients and analyzing patient samples for presence of methylated DNA and optionally particular gene mutations. In some embodiments, analysis results are correlated with clinical outcome measures such as risk of bladder cancer recurrence.

2. 发明专利

SG10201709537PA GENE EXPRESSION PROFILE ALGORITHM FOR CALCULATING A RECURRENCE SCORE FOR A PATIENT WITH KIDNEY CANCER 未知
公开(公告)号：SG10201709537PA
公开(公告)日：2017-12-28
申请号：SG10201709537P
申请日：2014-05-29
申请人： GENOMIC HEALTH INC
发明人： SHAK STEVEN , WATSON GEORGE ANDREW , CRAGER MICHAEL R , MADDALA TARA , LOPATIN MARGARITA , GODDARD AUDREY , KNEZEVIC DEJAN , SVEDMAN CHRISTER
摘要： The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The present invention also provides methods of obtaining a quantitative score for a patient with kidney cancer based on measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The genes may be grouped into functional gene subsets for calculating the quantitative score and the gene subsets may be weighted according to their contribution to cancer recurrence.

3. 发明申请

WO2013130465A3 GENE EXPRESSION MARKERS FOR PREDICTION OF EFFICACY OF PLATINUM-BASED CHEMOTHERAPY DRUGS 审中-公开
标题翻译：用于预测基于白蛋白的化疗药物的基因表达标记
公开(公告)号：WO2013130465A3
公开(公告)日：2015-07-02
申请号：PCT/US2013027789
申请日：2013-02-26
申请人： GENOMIC HEALTH INC
发明人： SHAK STEVE , LEE MARK , CRAGER MICHAEL , LOPATIN MARGARITA , BAKER JOFFRE B , CLARK-LANGONE KIM , PELHAM ROBERT J
IPC分类号： C12Q1/68 , G01N33/574
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/156
摘要： Methods for predicting the efficacy of a treatment with a platinum-based chemotherapy drug in a patient with cancer are disclosed. The methods generally involve determining an expression level of a gene product that correlates with responsiveness to treatment with a platinum-based chemotherapy drug, which may be oxaliplatin. The cancer may be colorectal cancer.
摘要翻译：公开了用于预测在铂类化疗药物治疗癌症患者中的疗效的方法。所述方法通常涉及确定与可以是奥沙利铂的基于铂的化疗药物的治疗反应性相关的基因产物的表达水平。癌症可能是结肠直肠癌。

4. 发明专利

CA3093128C GENE EXPRESSION PROFILE ALGORITHM FOR CALCULATING A RECURRENCE SCORE FOR A PATIENT WITH KIDNEY CANCER 未知
公开(公告)号：CA3093128C
公开(公告)日：2023-01-03
申请号：CA3093128
申请日：2014-05-29
申请人： GENOMIC HEALTH INC
发明人： SHAK STEVEN , WATSON GEORGE ANDREW , CRAGER MICHAEL R , MADDALA TARA , LOPATIN MARGARITA , GODDARD AUDREY , KNEZEVIC DEJAN , SVEDMAN CHRISTER
IPC分类号： G16B25/10 , C12Q1/6809 , C12Q1/6851
摘要： ABSTRACT The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The present invention also provides methods of obtaining a quantitative score for a patient with kidney cancer based on measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The genes may be grouped into functional gene subsets for calculating the quantitative score and the gene subsets may be weighted according to their contribution to cancer recurrence. Date Recue/Date Received 2020-09-15

5. 发明专利

NZ752676A Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer 未知
公开(公告)号：NZ752676A
公开(公告)日：2021-05-28
申请号：NZ75267614
申请日：2014-05-29
申请人： GENOMIC HEALTH INC
发明人： SHAK STEVEN , WATSON GEORGE ANDREW , CRAGER MICHAEL R , MADDALA TARA , LOPATIN MARGARITA , GODDARD AUDREY , KNEZEVIC DEJAN , SVEDMAN CHRISTER
IPC分类号： C12Q1/68
摘要： The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The present invention also provides methods of obtaining a quantitative score for a patient with kidney cancer based on measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The genes may be grouped into functional gene subsets for calculating the quantitative score and the gene subsets may be weighted according to their contribution to cancer recurrence. In particular, the present invention relates to the gene subset EIF4EBP1, LMNB1 and TUBB2A assigned to the cell growth/division gene group.

6. 发明专利

SG11201909113VA DNA METHYLATION AND MUTATIONAL ANALYSIS METHODS FOR BLADDER CANCER SURVEILLANCE 未知
公开(公告)号：SG11201909113VA
公开(公告)日：2019-10-30
申请号：SG11201909113V
申请日：2018-05-17
申请人： GENOMIC HEALTH INC
发明人： LOPATIN MARGARITA , TSIATIS ATHANASIOS , SILK CHRISTOPHER N , MILLER DAVID P , CRAGER MICHAEL , FEBBO PHILLIP , KNEZEVIC DEJAN
IPC分类号： C12Q1/6886
摘要： 1 0.2 0.3 OA 0.5 0.6 0.7 0.8 0.9 P091.444oD quantile speciriCitc , 52 .41 ?•i , 77.9% (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 22 November 2018 (22.11.2018) WIP0 I PCT Hu omit VIII °nolo olotill ommoolio iflo oimIE (10) International Publication Number WO 2018/213550 Al (51) International Patent Classification: C12Q 1/6886 (2018.01) (21) International Application Number: PCT/US2018/033146 (22) International Filing Date: 17 May 2018 (17.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/508,274 18 May 2017 (18.05.2017) US (71) Applicant: GENOMIC HEALTH, INC. [US/US]; 301 Penobscot Drive, Redwood City, California 94063 (US). (72) Inventors: LOPATIN, Margarita; 301 Penobscot Dri- ve, Redwood City, California 94603 (US). TSIATIS, Athanasios; 301 Penobscot Drive, Redwood City, Califor- nia 94603 (US). SILK, Christopher N.; 301 Penobscot Drive, Redwood City, California 94603 (US). MILLER, David P.; 1080 Peralta Avenue, Albany, California 94706 (US). CRAGER, Michael; 301 Penobscot Drive, Red- wood City, California 94603 (US). FEBBO, Phillip; 301 Penobscot Drive, Redwood City, California 94603 (US). KNEZEVIC, Dej an; 301 Penobscot Drive, Redwood City, California 94603 (US). (74) Agent: DOHERTY, Elizabeth A. et al.; 125 Cambridge Park Drive, Suite 301, Cambridge, Massachusetts 02140 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (54) Title: DNA METHYLATION AND MUTATIONAL ANALYSIS METHODS FOR BLADDER CANCER SURVEILLANCE 1.00 099 0.98 0.97 0.96 High Risk Recur t11 1 \"I 1.0 0.8 0.6 0.4 02 99 . 7% 98.8% 0.05 0.0 0.1 0.2 0.3 0.4 0.5 0.8 0.7 0.8 69 0.0 Population qthar669 Sensith.My 1.0 0.6 0.8 0.6 0.6 0.4 0) 0.2 w. a2 04 96.596 0.0 0.0 \" 0.0 0.1 02 0.3 04 0.5 D.6 0.7 0.8 0.9 1.0 popw.ation qumUe 0.0 01 0.2 201 0.4 6.5 OA 0.7 0.6 0.9 1.0 Popti;aton quantilt., Fig. 1 00 (57) : The present disclosure relates to methods of monitoring bladder cancer patients and analyzing patient samples for O presence of methylated DNA and optionally particular gene mutations. In some embodiments, analysis results are correlated with clinical outcome measures such as risk of bladder cancer recurrence. C [Continued on next page] WO 2018/213550 Al MIDEDIMOHNIIME1010010ElliOMMINUMEHOIS EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))

7. 发明专利

NZ711680A Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer 未知
公开(公告)号：NZ711680A
公开(公告)日：2021-05-28
申请号：NZ71168014
申请日：2014-05-29
申请人： GENOMIC HEALTH INC
发明人： SHAK STEVEN , WATSON GEORGE ANDREW , CRAGER MICHAEL R , MADDALA TARA , LOPATIN MARGARITA , GODDARD AUDREY , KNEZEVIC DEJAN , SVEDMAN CHRISTER
IPC分类号： C12Q1/68
摘要： The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The present invention also provides methods of obtaining a quantitative score for a patient with kidney cancer based on measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The genes may be grouped into functional gene subsets for calculating the quantitative score and the gene subsets may be weighted according to their contribution to cancer recurrence. In particular, the gene subsets are: a vascular normalization gene group comprising APOLD1, EDNRB, NOS3 and PPAP2B; an immune response gene group comprising CCL5, CEACAM1 and CX3CL1; a cell growth/division gene group comprising EIF4EBP1, LMNB1 and TUBB2A; and IL-6.

8. 发明专利

CA2903878C GENE EXPRESSION PROFILE ALGORITHM FOR CALCULATING A RECURRENCE SCORE FOR A PATIENT WITH KIDNEY CANCER 未知
公开(公告)号：CA2903878C
公开(公告)日：2020-10-27
申请号：CA2903878
申请日：2014-05-29
申请人： GENOMIC HEALTH INC
发明人： SHAK STEVEN , WATSON GEORGE ANDREW , CRAGER MICHAEL R , MADDALA TARA , LOPATIN MARGARITA , GODDARD AUDREY , KNEZEVIC DEJAN , SVEDMAN CHRISTER
IPC分类号： G16B25/10 , C12Q1/6809 , C12Q1/6851 , G16B20/00
摘要： The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The present invention also provides methods of obtaining a quantitative score for a patient with kidney cancer based on measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The genes may be grouped into functional gene subsets for calculating the quantitative score and the gene subsets may be weighted according to their contribution to cancer recurrence.

9. 发明专利

AU2014274135B2 Gene expression profile algorithm for calculating a recurrence score for a patient with kidney cancer 未知
公开(公告)号：AU2014274135B2
公开(公告)日：2020-04-09
申请号：AU2014274135
申请日：2014-05-29
申请人： GENOMIC HEALTH INC
发明人： SHAK STEVEN , WATSON GEORGE ANDREW , CRAGER MICHAEL R , MADDALA TARA , LOPATIN MARGARITA , GODDARD AUDREY , KNEZEVIC DEJAN , SVEDMAN CHRISTER
IPC分类号： C12Q1/68
摘要： The present invention provides algorithm-based molecular assays that involve measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The present invention also provides methods of obtaining a quantitative score for a patient with kidney cancer based on measurement of expression levels of genes from a biological sample obtained from a kidney cancer patient. The genes may be grouped into functional gene subsets for calculating the quantitative score and the gene subsets may be weighted according to their contribution to cancer recurrence.

10. 发明专利

SG10201912359XA DNA METHYLATION AND MUTATIONAL ANALYSIS METHODS FOR BLADDER CANCER SURVEILLANCE 未知
公开(公告)号：SG10201912359XA
公开(公告)日：2020-02-27
申请号：SG10201912359X
申请日：2018-05-17
申请人： GENOMIC HEALTH INC
发明人： LOPATIN MARGARITA , TSIATIS ATHANASIOS , SILK CHRISTOPHER N , MILLER DAVID P , CRAGER MICHAEL , FEBBO PHILLIP , KNEZEVIC DEJAN
摘要： The present disclosure relates to methods of monitoring bladder cancer patients and analyzing patient samples for presence of methylated DNA and optionally particular gene mutations. In some embodiments, analysis results are correlated with clinical outcome measures such as risk of bladder cancer recurrence.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式